Far far away, behind the word mountains, far from the countries Vokalia and Consonantia, there live the blind texts. Separated they live in Bookmarksgrove right at the coast
Far far away, behind the word mountains, far from the countries Vokalia and Consonantia, there live the blind texts. Separated they live in Bookmarksgrove right at the coast
Far far away, behind the word mountains, far from the countries Vokalia and Consonantia, there live the blind texts. Separated they live in Bookmarksgrove right at the coast
Paragraph
Brochure
Brochure
The NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, allowing for unprecedented biomarker detection and quantitation. By leveraging a proprietary sequential immunocomplex capture and release mechanism and the latest advances in Next-Generation Sequencing (NGS), the NULISA technology provides both ultra-high sensitivity and scalable multiplexing.
Ultra-high attomolar sensitivity and lower limits of detection for the discovery and detection of critical biomarkers.
With single plex up to 7 logs and multiplex up to 12 logs of dynamic range, NULISA enables quantitation across a broad range of biological expression levels without the need for dilution.
Flexible, scalable chemistry provides the ability to focus in on a single target, or multiplex hundreds to potentially thousands of targets in a single sample on one platform. NULISA assays maintain performance from single qPCR to multiplex NGS analyses.
Despite significant progress over the past 50 years, much of the human plasma proteome remains undetectable by existing protein analysis technologies.
Alamar Biosciences is a proteomics company empowering researchers to interrogate the proteome with unprecedented breadth, depth, and high-throughput precision.
With best-in-class attomolar sensitivity and up to 12-log dynamic range, NULISA technology enables accurate detection of highly multiplexed protein biomarkers from a 25 µl liquid biopsy specimen.
Translational scientists can seamlessly and confidently transition across their biomarker discovery and validation journey using the same platform. New insights from large cohorts and population studies will revolutionize our understanding of the human proteome and unlock its full potential for improving human health.